| Carcinoma breast stage IV
Perjeta vs Orserdu
Side-by-side clinical, coverage, and cost comparison for carcinoma breast stage iv.Deep comparison between: Perjeta vs Orserdu with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOrserdu has a higher rate of injection site reactions vs Perjeta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Orserdu but not Perjeta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Perjeta
Orserdu
At A Glance
IV infusion
Every 3 weeks
HER2/neu receptor antagonist
Oral
Daily
Estrogen receptor antagonist
Indications
- Carcinoma breast stage IV
- Locally Advanced Breast Carcinoma
- Inflammatory Breast Carcinoma
- Early Stage HER2-Positive Breast Carcinoma
- Carcinoma breast stage IV
Dosing
Carcinoma breast stage IV Initial 840 mg IV over 60 min, then 420 mg IV every 3 weeks; administered with trastuzumab and docetaxel.
Locally Advanced Breast Carcinoma, Inflammatory Breast Carcinoma, Early Stage HER2-Positive Breast Carcinoma Initial 840 mg IV, then 420 mg IV every 3 weeks with trastuzumab and chemotherapy; neoadjuvant: 3-6 preoperative cycles followed by postoperative continuation to complete 1 year; adjuvant: 1 year total (up to 18 cycles), starting Day 1 of first taxane-containing cycle.
Carcinoma breast stage IV 345 mg taken orally once daily with food until disease progression or unacceptable toxicity; dose reductions to 258 mg or 172 mg once daily for adverse reactions.
Contraindications
- Known hypersensitivity to pertuzumab or any of its excipients
—
Adverse Reactions
Most common (>30%) diarrhea, alopecia, neutropenia, nausea, fatigue, rash, peripheral neuropathy
Serious neutropenia, febrile neutropenia, leukopenia, diarrhea, peripheral neuropathy, anemia, asthenia, fatigue
Most common (>=10%) Musculoskeletal pain, nausea, increased cholesterol, increased AST, increased triglycerides, fatigue, decreased hemoglobin, vomiting, increased ALT, decreased sodium, increased creatinine, decreased appetite, diarrhea, headache, constipation, abdominal pain, hot flush, dyspepsia.
Serious Musculoskeletal pain, nausea.
Pharmacology
Pertuzumab is a HER2/neu receptor antagonist that blocks ligand-dependent heterodimerization of HER2 with other HER family members (EGFR, HER3, HER4), inhibiting MAP kinase and PI3K signaling pathways to cause cell growth arrest and apoptosis; it also mediates antibody-dependent cell-mediated cytotoxicity (ADCC).
Estrogen receptor antagonist that binds to ERalpha and inhibits 17beta-estradiol mediated cell proliferation through ERalpha protein degradation via the proteasomal pathway, with demonstrated antitumor activity in ESR1-mutated and CDK4/6 inhibitor-resistant ER+ HER2- breast cancer models.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Perjeta
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
Orserdu
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Perjeta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Orserdu
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Perjeta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Orserdu
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Perjeta.
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PerjetaView full Perjeta profile
OrserduView full Orserdu profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.